Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Tuesday that it has received US Food and Drug Administration (FDA) approval for RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) as a first-line treatment for patients with EGFR-mutated advanced lung cancer.
This combination therapy is the first chemotherapy-free regimen to demonstrate superior progression-free survival compared to osimertinib.
The approval is based on data from the Phase 3 MARIPOSA study, which showed a 30% reduced risk of disease progression or death with RYBREVANT plus LAZCLUZE versus osimertinib. The combination also extended median duration of response by nine months.
Lung cancer is a leading cause of cancer deaths globally. Of patients with EGFR-mutated non-small cell lung cancer (NSCLC), 25-39% never receive second-line therapy due to disease progression and lack of treatment options.
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Sanofi and Regeneron's Dupixent approved for COPD in China
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi